Tenth Edition of The Merck Veterinary Manual Debuts
October 13, 2010 7:08 am ET
New Book to Feature Hundreds of Full-Color Images
Merck announced today that the Tenth Edition of The Merck Veterinary
Manual, a comprehensive reference on animal health for veterinary
professionals, has now been released.
First published in 1955, The Merck Veterinary Manual addresses
diagnosis, treatment, and prevention of diseases in companion, food,
exotic, wild, and laboratory animals. Over 400 veterinary experts from
19 countries contributed to this latest edition which is published as an
educational partnership with Merial Limited.
“The goal of The Merck Veterinary Manual has always been to
provide concise and authoritative information on all common diseases of
animals likely to be seen by veterinarians,” said editor of The
Merck Veterinary Manual, Cynthia M. Kahn, B.A., M.A., of Merial
Limited. “This new edition reflects both the remarkable advances in
veterinary science and the emergence of new pathogens and diseases since
the previous edition.”
For the first time, The Merck Veterinary Manual, a hardcover
book, features hundreds of full-color graphics, including illustrations,
photomicrographs, and radiographic, ultrasonographic, and endoscopic
images. Every chapter of the new manual has been reviewed and updated to
reflect the latest findings in medicine and clinical practice.
Ten new chapters have been added to provide information on emerging
issues of importance to veterinarians, including the cloning of domestic
animals, complementary and alternative veterinary medicine, and diseases
and disorders such as equine metabolic syndrome, disorders of potassium
metabolism, seminal vesiculitis in bulls, and pseudopregnancy in goats.
The Tenth Edition reflects the increasing knowledge base regarding
exotic and laboratory animals with expanded coverage of pet birds, fish,
ratites, reptiles, and rodents.
A chapter on African hedgehogs has been added to reflect their growing
popularity as pets.
The extensive Zoonoses reference table has also been updated with new
introductory material, recent zoonoses, and cross references to more
complete discussions. In addition, the zoonotic potential of veterinary
diseases has been highlighted throughout the text. Other sections that
have been extensively revised include toxicology, immunology, and
The pharmacology section includes content on drug actions and
pharmacodynamics, veterinary dosage forms and delivery systems, and
chemical residues in food. More than 60 tables in this section provide
information on topics such as drug treatments and potencies, laboratory
tests, and parasites.
Published as a service to the scientific community, The Tenth Edition of The
Merck Veterinary Manual sells for $60.00 and is available at leading
bookstores, by calling toll-free at 877-762-2974, or via the Internet at www.merckbooks.com.
Merck also publishes The Merck/Merial Manual for Pet Health, The
Merck Manual of Diagnosis and Therapy, The Merck Manual of Patient
Symptoms, The Merck Manual Home Health Handbook, The Merck Manual of
Health and Aging, and The Merck Index.
Today’s Merck is a global healthcare leader working to help the world be
well. Merck is known as MSD outside the United States and Canada.
Through our prescription medicines, vaccines, biologic therapies, and
consumer care and animal health products, we work with customers and
operate in more than 140 countries to deliver innovative health
solutions. We also demonstrate our commitment to increasing access to
healthcare through far-reaching policies, programs and partnerships. For
more information, visit www.merck.com.
Merck Forward-Looking Statement
This news release includes “forward-looking statements” within the
meaning of the safe harbor provisions of the United States Private
Securities Litigation Reform Act of 1995. Such statements may include,
but are not limited to, statements about the benefits of the merger
between Merck and Schering-Plough, including future financial and
operating results, the combined company’s plans, objectives,
expectations and intentions and other statements that are not historical
facts. Such statements are based upon the current beliefs and
expectations of Merck’s management and are subject to significant risks
and uncertainties. Actual results may differ from those set forth in the
The following factors, among others, could cause actual results to
differ from those set forth in the forward-looking statements: the
possibility that the expected synergies from the merger of Merck and
Schering-Plough will not be realized, or will not be realized within the
expected time period; the impact of pharmaceutical industry regulation
and health care legislation; the risk that the businesses will not be
integrated successfully; disruption from the merger making it more
difficult to maintain business and operational relationships; Merck’s
ability to accurately predict future market conditions; dependence on
the effectiveness of Merck’s patents and other protections for
innovative products; the risk of new and changing regulation and health
policies in the U.S. and internationally and the exposure to litigation
and/or regulatory actions.
Merck undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or
otherwise. Additional factors that could cause results to differ
materially from those described in the forward-looking statements can be
found in Merck’s 2009 Annual Report on Form 10-K and the company’s other
filings with the Securities and Exchange Commission (SEC) available at
the SEC’s Internet site (www.sec.gov).